271 related articles for article (PubMed ID: 34933916)
1. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.
Vitale A; Svegliati-Baroni G; Ortolani A; Cucco M; Dalla Riva GV; Giannini EG; Piscaglia F; Rapaccini G; Di Marco M; Caturelli E; Zoli M; Sacco R; Cabibbo G; Marra F; Mega A; Morisco F; Gasbarrini A; Foschi FG; Missale G; Masotto A; Nardone G; Raimondo G; Azzaroli F; Vidili G; Oliveri F; Pelizzaro F; Ramirez Morales R; Cillo U; Trevisani F; Miele L; Marchesini G; Farinati F;
Gut; 2023 Jan; 72(1):141-152. PubMed ID: 34933916
[TBL] [Abstract][Full Text] [Related]
2. MAFLD: an optimal framework for understanding liver cancer phenotypes.
Crane H; Gofton C; Sharma A; George J
J Gastroenterol; 2023 Oct; 58(10):947-964. PubMed ID: 37470858
[TBL] [Abstract][Full Text] [Related]
3. Hepatectomy for Metabolic Associated Fatty Liver Disease (MAFLD) related HCC: Propensity case-matched analysis with viral- and alcohol-related HCC.
Conci S; Cipriani F; Donadon M; Marchitelli I; Ardito F; Famularo S; Perri P; Iaria M; Ansaloni L; Zanello M; La Barba G; Patauner S; Pinotti E; Molfino S; Germani P; Romano M; Sciannamea I; Ferrari C; Manzoni A; Troci A; Fumagalli L; Delvecchio A; Floridi A; Memeo R; Chiarelli M; Crespi M; Zimmitti G; Griseri G; Antonucci A; Zanus G; Tarchi P; Baiocchi GL; Zago M; Frena A; Ercolani G; Jovine E; Maestri M; Valle RD; Grazi GL; Romano F; Giuliante F; Torzilli G; Aldrighetti L; Ruzzenente A;
Eur J Surg Oncol; 2022 Jan; 48(1):103-112. PubMed ID: 34325939
[TBL] [Abstract][Full Text] [Related]
4. Correlation analysis of metabolic characteristics and the risk of metabolic-associated fatty liver disease - related hepatocellular carcinoma.
Xie X; Zheng M; Guo W; Zhou Y; Xiang Z; Li Y; Yang J
Sci Rep; 2022 Aug; 12(1):13969. PubMed ID: 35978032
[TBL] [Abstract][Full Text] [Related]
5. Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study.
Johira Y; Nakahara T; Kinami T; Yamasaki S; Kosaka M; Shirane Y; Miura R; Murakami S; Yano S; Amioka K; Naruto K; Ando Y; Kosaka Y; Kodama K; Uchikawa S; Fujino H; Ono A; Murakami E; Okamoto W; Yamauchi M; Kawaoka T; Hayes CN; Tsuge M; Imamura M; Aikata H; Oka S
BMC Gastroenterol; 2023 Jun; 23(1):222. PubMed ID: 37380950
[TBL] [Abstract][Full Text] [Related]
6. Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma.
Chen VL; Yeh ML; Yang JD; Leong J; Huang DQ; Toyoda H; Chen YL; Guy J; Maeda M; Tsai PC; Huang CF; Yasuda S; Le AK; Dang H; Giama NH; Ali HA; Zhang N; Wang X; Jun DW; Tseng CH; Hsu YC; Huang JF; Dai CY; Chuang WL; Zhu Q; Dan YY; Schwartz M; Roberts LR; Yu ML; Nguyen MH
Hepatol Commun; 2021 Jan; 5(1):122-132. PubMed ID: 33437906
[TBL] [Abstract][Full Text] [Related]
7. Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres.
Cazzagon N; Trevisani F; Maddalo G; Giacomin A; Vanin V; Pozzan C; Poggio PD; Rapaccini G; Nolfo AM; Benvegnù L; Zoli M; Borzio F; Giannini EG; Caturelli E; Chiaramonte M; Foschi FG; Cabibbo G; Felder M; Ciccarese F; Missale G; Baroni GS; Morisco F; Pecorelli A; Farinati F;
Liver Int; 2013 Oct; 33(9):1420-7. PubMed ID: 23758775
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
9. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma.
Kumar R; Goh BG; Kam JW; Chang PE; Tan CK
Clin Mol Hepatol; 2020 Apr; 26(2):196-208. PubMed ID: 31914720
[TBL] [Abstract][Full Text] [Related]
10. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period.
Pais R; Fartoux L; Goumard C; Scatton O; Wendum D; Rosmorduc O; Ratziu V
Aliment Pharmacol Ther; 2017 Nov; 46(9):856-863. PubMed ID: 28857208
[TBL] [Abstract][Full Text] [Related]
11. The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study.
Chen YG; Yang CW; Chung CH; Ho CL; Chen WL; Chien WC
Hepatol Int; 2022 Aug; 16(4):807-816. PubMed ID: 35064545
[TBL] [Abstract][Full Text] [Related]
12. Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients.
Kim MN; Han K; Yoo J; Hwang SG; Zhang X; Ahn SH
Int J Cancer; 2023 Oct; 153(8):1448-1458. PubMed ID: 37439276
[TBL] [Abstract][Full Text] [Related]
13. Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets.
Chen Y; Wang W; Morgan MP; Robson T; Annett S
Front Endocrinol (Lausanne); 2023; 14():1148934. PubMed ID: 37361533
[TBL] [Abstract][Full Text] [Related]
14. Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma.
Song BG; Choi SC; Goh MJ; Kang W; Sinn DH; Gwak GY; Paik YH; Choi MS; Lee JH; Paik SW
JHEP Rep; 2023 Sep; 5(9):100810. PubMed ID: 37538246
[TBL] [Abstract][Full Text] [Related]
15. NAFLD and MAFLD as emerging causes of HCC: A populational study.
Myers S; Neyroud-Caspar I; Spahr L; Gkouvatsos K; Fournier E; Giostra E; Magini G; Frossard JL; Bascaron ME; Vernaz N; Zampaglione L; Negro F; Goossens N
JHEP Rep; 2021 Apr; 3(2):100231. PubMed ID: 33748726
[TBL] [Abstract][Full Text] [Related]
16. Clinical features and management issues of NAFLD-related HCC: what we know so far.
Pugliese N; Alfarone L; Arcari I; Giugliano S; Parigi TL; Rescigno M; Lleo A; Aghemo A
Expert Rev Gastroenterol Hepatol; 2023 Jan; 17(1):31-43. PubMed ID: 36576057
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Hepatocellular Carcinoma in Patients with Cryptogenic Versus Hepatitis B Etiology: A Study of 1079 Cases Over 3 Decades.
Liew ZH; Goh GB; Hao Y; Chang PE; Tan CK
Dig Dis Sci; 2019 Feb; 64(2):585-590. PubMed ID: 30327962
[TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.
Younossi Z; Stepanova M; Ong JP; Jacobson IM; Bugianesi E; Duseja A; Eguchi Y; Wong VW; Negro F; Yilmaz Y; Romero-Gomez M; George J; Ahmed A; Wong R; Younossi I; Ziayee M; Afendy A;
Clin Gastroenterol Hepatol; 2019 Mar; 17(4):748-755.e3. PubMed ID: 29908364
[TBL] [Abstract][Full Text] [Related]
19. MAFLD enhances clinical practice for liver disease in the Asia-Pacific region.
Kawaguchi T; Tsutsumi T; Nakano D; Eslam M; George J; Torimura T
Clin Mol Hepatol; 2022 Apr; 28(2):150-163. PubMed ID: 34753279
[TBL] [Abstract][Full Text] [Related]
20. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
